lowRISC Collaborates with Industry Leaders to Create OpenTitan
lowRISC C.I.C., the open source silicon and tools collaborative engineering company, today announced that it has partnered with ETH Zürich, Google, G+D Mobile Security, Nuvoton Technology and Western Digital in support of OpenTitan, an open source hardware root of trust (RoT) reference design and integration guidelines that enable chip producers and platform providers to build transparently implemented, high-quality hardware RoT chips tailored for data center servers and other devices.
Security begins with infrastructure, and OpenTitan will help ensure root of trust in hardware, transparently implemented, at the foundation for a multitude of devices such as server motherboards, network cards, routers and IoT. Adopters of this framework can inspect and contribute to OpenTitan’s register-transfer level (RTL) design, firmware, and documentation, helping to build more transparent, trustworthy hardware RoT chips for everyone.
OpenTitan is stewarded by lowRISC, which provides a neutral home for collaborative engineering to develop and maintain open source silicon designs and tools for the long term. As with open source software, open silicon provides a deep level of transparency and therefore auditability, as well as enabling innovation. Shared open infrastructure technology permits focus on product differentiation, with shared costs and substantially reduced overall risk.
The Ibex RISC-V processor core, which was originally developed by ETH Zürich as zero-riscy and contributed to lowRISC earlier this year, forms a key component for OpenTitan. lowRISC is committed to raising the bar for quality in open silicon via a methodical approach that combines the development and use of best practices and coding standards, with rigorous testing and verification.
Key benefits of OpenTitan for chip manufacturers and platform providers include:
- Transparent: Adopters can inspect and contribute to OpenTitan’s design, firmware, and documentation, helping to build more transparent, trustworthy hardware RoT chips that benefit everyone.
- High-quality: OpenTitan’s goal is to build and maintain a high-quality and logically secure RTL design, firmware, and documentation. The project is staffed by expert engineers focused on rigorous design validation and technical documentation, all based on key learnings from designing Google’s Titan chips.
- Flexible: Adopters can increase their total addressable market and reduce costs by using a single platform-agnostic hardware RoT design that can be integrated in data center servers, peripherals, and any other hardware platforms.
“We believe collaboratively developed open source silicon designs provide the flexible, cost effective base needed for future generations of secure hardware products,” said Alex Bradbury, lowRISC CTO. “The lowRISC not-for-profit structure combined with full stack engineering capabilities in-house, enables us to manage high quality projects like OpenTitan, and we look forward to developing this partnership and new ones in the future.”
“At lowRISC, our mission is to establish a vibrant ecosystem around open silicon designs and to help lower the barrier to producing custom chips,” said Gavin Ferris, lowRISC CIC board member. “Creating an ecosystem of like-minded organizations focused on the goal of improving transparency around chips helps increase trust in the overall security of the infrastructure on which software runs. With OpenTitan, enterprise organizations and consumers alike will benefit from services built on a more secure infrastructure that is anchored in transparently implemented OpenTitan chips.”
“Customers are asked to put faith in proprietary hardware RoT chips for their mission-critical systems without the ability to fully understand, inspect and therefore trust them,” said Dominic Rizzo, OpenTitan Lead at Google and lowRISC’s OpenTitan Project Director. “By creating OpenTitan with the broader hardware and academic community, we can leverage the experience and security principles used to create Google’s own Titan chips to make hardware RoT designs more transparent, inspectable, and accessible to the rest of the industry. Security should never be built on opacity.”
Collaboration is fundamental to open silicon and at the core of everything that lowRISC does, bringing to projects a deep understanding of open source licensing, contributor models and community building, and providing a uniquely positioned engineering capability.
About lowRISC
lowRISC C.I.C. is a not-for-profit company that aims to demonstrate, promote and support the use of open-source hardware - bringing the benefits of open-source to the hardware world. We are producing high-quality, security-focused, open, and flexible IP. Our expertise includes the LLVM Compiler, novel hardware security extensions and RISC-V tools, hardware and processor design.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191105005089/en/
Contact information
Andrew Back
lowRISC
press@lowrisc.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
